#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary amyloidosis Ewing's sarcoma recurrent Neuroendocrine carcinoma metastatic Ocular myasthenia Haematological malignancy Congenital pseudarthrosis Neurofibromatosis Asthma Inflammatory myofibroblastic tumour Dent's disease Small intestine adenocarcinoma Porphyria non-acute Congenital myopathy Myotonic dystrophy Hypoparathyroidism More trials…

    Learn about Rare Diseases

    Optic glioma MELAS syndrome – Basic Information Sarcoidosis – Life with Disease Friedreich’s ataxia – Basic Information Mucopolysaccharidosis I – Diagnostics Progressive multifocal leukoencephalopathy Fragile X syndrome – Treatment Primary hyperoxaluria – Diagnostics Gastrointestinal stromal tumour – Treatment Extranodal marginal zone B-cell lymphoma (MALT type) – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ubiquinol Mirabegron Demeclocycline Hydrochloride Azd5863 Riboflavin Sodium Phosphate Gallium Citrate Ga-68 Sultiame Sotalol Metoprolol Resomelagon Foscarnet Loperamide Hydrochloride Guanfacine Cls12311 IDROXIOLEIC ACID CYCLIZINE HYDROCHLORIDE F125/10 SURVODUTIDE Cefepime Hydrochloride OMTX705 More therapies…

    Learn about Your Condition

    Portal hypertension Hyperchylomicronaemia Meningioma Thalassaemia Post-traumatic stress disorder Pleomorphic leiomyosarcoma Connective tissue disorder Diverticulitis Mixed-type liposarcoma Tumour thrombosis Glucose tolerance impaired Combined immunodeficiency Arterial tortuosity syndrome Anogenital dysplasia Anal fistula More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Frisius

Frisius

Henri Dunantweg 2, Heerenveen, 8934 AD, Netherlands

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Induction Chemotherapy with Irinotecan, Folinic Acid, Fluorouracil, and Oxaliplatin for Patients with High-Risk Locally Advanced Rectal Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Fluorouracil
    • Folinic Acid
    • Irinotecan Hydrochloride Trihydrate
    The Netherlands

  • Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Exemestane
    • Abemaciclib
    • Fulvestrant
    Austria Belgium France Germany Greece Italy +2

  • Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Evolocumab
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Study on Obinutuzumab and Venetoclax for Elderly Patients with Chronic Lymphocytic Leukemia Unfit for Standard Treatments

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Obinutuzumab
    • Venetoclax
    The Netherlands

  • Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Type IIa hyperlipidaemia
    Denmark France Germany Hungary Italy The Netherlands +3

  • Study on Semaglutide for Achieving Sinus Rhythm in Patients with Obesity and Persistent Atrial Fibrillation

    Not recruiting

    3 1
    Investigated Diseases:
    • Palpitations
    • Atrial fibrillation
    • Obesity
    Investigated Drugs:
    • Semaglutide
    The Netherlands

  • Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Malignant melanoma stage III
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    France Italy The Netherlands Poland

  • Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Depemokimab
    • Mepolizumab
    • Benralizumab
    Austria Finland France Germany Ireland Italy +6

  • Study on Preventing Acute Kidney Injury in Cardiac Surgery Patients Using Dapagliflozin

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Dapagliflozin
    The Netherlands

  • Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Atorvastatin
    • Rosuvastatin
    • Inclisiran
    Austria Belgium Bulgaria Croatia Czechia Denmark +18
Previous Page
1 … 8 9 10 11
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!